1. Show article details.

    Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal

    GlobeNewswire – 8:30 AM ET 04/15/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of three key executives in high priority strategic roles integral to the preparation for the potential Zerenex™ product launch.

  2. Show article details.

    Keryx Biopharmaceuticals Announces Zerenex(TM) (Ferric Citrate Coordination Complex) Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting

    GlobeNewswire – 8:30 AM ET 04/09/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Phase 2 clinical results of Zerenex™ in non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26, 2014 in Las Vegas, NV. This presentation, ent...

  3. Show article details.

    Health Care Sector Stocks under Review -- Research on Sanofi, Impax Laboratories, Keryx Biopharma, and Rigel Pharma

    PR Newswire – 1:59 PM ET 04/08/2014

    LONDON, April 8, 2014 The trading session on Monday, April 07, 2014 ended on a lower note as the S&P 500 finished the session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at 4,079.75, down 1.16%. The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative. SOURCE Investor-Edge.

  4. Show article details.

    Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)

    GlobeNewswire – 8:30 AM ET 04/02/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that the European Medicines Agency has determined that the Company's Marketing Authorization Application seeking the approval of Zerenex™ as a treatment for hyperphosphatemia in patients with chronic kidney disease, including dialysis- and non-dialysis-dependent CKD, is valid.

  5. Show article details.

    Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies

    Business Wire – 8:00 AM ET 04/01/2014

    Foresite Capital, a growth equity firm focused on late-stage healthcare investing, today announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital commitments. "Since founding Foresite Capital in 2011, we have seen several portfolio companies grow into billion dollar plus businesses," said Jim Tananbaum, founder and CEO of Foresite Capital.

  6. Show article details.

    Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories

    PR Newswire – 8:41 AM ET 03/19/2014

    LONDON, March 19, 2014 On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. http://www.investor-edge.com/336-register.

  7. Show article details.

    Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA

    PR Newswire – 8:00 AM ET 03/19/2014

    NEW YORK, March 19, 2014 Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (KERX), WellCare Health Plans, Inc. (WCG), Zogenix, Inc. (ZGNX), Orexigen Therapeutics, Inc. (OREX), and XOMA Corporation.

  8. Show article details.

    Keryx Biopharmaceuticals' Zerenex(TM) Data Selected for Poster Presentation at the AMCP's 26th Annual Meeting and Expo

    GlobeNewswire – 8:30 AM ET 03/17/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that data highlighting the potential pharmacoeconomic benefit of Zerenex™, the Company's drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy's 26th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Cent...

  9. Show article details.

    Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results

    GlobeNewswire – 4:30 PM ET 03/12/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced its financial results for the fourth quarter and year ended December 31, 2013.

  10. Show article details.

    Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results

    GlobeNewswire – 4:30 PM ET 03/11/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December 31, 2013 and a business outlook for 2014.

  11. Show article details.

    Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency

    GlobeNewswire – 8:30 AM ET 03/10/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced it has submitted a Marketing Authorization Application to the European Medicines Agency, seeking the approval of Zerenex™ as a treatment for hyperphosphatemia in patients with chronic kidney disease, including dialysis- and non-dialysis dependent CKD.

  12. Show article details.

    Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences

    GlobeNewswire – 8:30 AM ET 02/26/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences: 34TH Annual Cowen and Company Health Care Conference Presentation Date: Monday, March 3rd, 2014 Presentation Time: 2:50 pm ET.

  13. Show article details.

    Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

    GlobeNewswire – 8:30 AM ET 02/18/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of Abraham Ceesay as Vice President of Marketing and Operations.

  14. Show article details.

    Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer

    GlobeNewswire – 8:30 AM ET 02/10/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced the appointment of Greg Madison as Executive Vice President and Chief Operating Officer.

  15. Show article details.

    Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

    GlobeNewswire – 8:30 AM ET 02/06/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City.

  16. Show article details.

    Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock

    PR Newswire – 7:42 PM ET 01/22/2014

    NEW YORK, Jan. 22, 2014 Keryx Biopharmaceuticals, Inc. (KERX) today announced the pricing of an underwritten public offering of common stock consisting of 6,900,000 shares at $14.50 per share. J.P. Morgan Securities LLC is acting as sole book-running manager in the offering.

  17. Show article details.

    Keryx Biopharmaceuticals, Inc. Announces $90 Million Proposed Public Offering of Common Stock

    PR Newswire – 4:19 PM ET 01/21/2014

    NEW YORK, Jan. 21, 2014 Keryx Biopharmaceuticals, Inc. (KERX) today announced that it has commenced a $90 million underwritten public offering of shares of its common stock. The securities described above are being offered by Keryx pursuant to a Form S-3 shelf registration statement previously filed with the Securities and Exchange Commission.

  18. Show article details.

    Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access

    GlobeNewswire – 8:30 AM ET 01/21/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced the appointment of Daniel W. Olmstead to the newly created position of Vice President, Payer Access.

  19. Show article details.

    Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan

    PR Newswire – 8:00 AM ET 01/17/2014

    NEW YORK, Jan. 17, 2014 Keryx Biopharmaceuticals, Inc. (KERX) today announced that its Japanese partner, Japan Tobacco Inc., has received manufacturing and marketing approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare.

  20. Show article details.

    Keryx Biopharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

    GlobeNewswire – 8:30 AM ET 01/07/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2014, in San Francisco. A live audio webcast of Mr. Bentsur's presentation will be accessible within the Media section of the Company's Website at http://www.keryx.com/webcasts-presentations.

Page:

Today's and Upcoming Events

  • May
    7

    KERX to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    13

    KERX Earnings Conference Call at 8:30 AM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.